Whalesbook
Novo Nordisk announced that its pill version of Ozempic (semaglutide) failed to slow Alzheimer's disease progression in two large studies. Patients showed no difference in cognitive decline, leading the Danish drugmaker to discontinue trial extensions. The news caused Novo shares to plunge, impacting its future outlook in the competitive obesity and diabetes market.